Institute for rational pharmacotherapy Home

INSTITUTE FOR RATIONAL PHARMACOTHERAPY (IRF)

The aim of the IRF is to promote the most rational use of current and future medicinal products with respect to both pharmacological and economical aspects. This aim is directed towards both primary and hospital care.

REVIEWS

Resolor (prucalopride)

27 November 2012

Eklira Genuair (aclidinium)

02 November 2012

Zoely (nomegestrolaecetate + estradiol)

10 September 2012

Alvesco inhalation spray (ciclesonide)

10 September 2012

Vimovo (naproxen 500 mg/esomeprazole 20 mg)

10 September 2012

Azyter eye drops

21 February 2012

Bydureon (exenatide)

Review of exenatide for weekly administration

30 November 2011

Trajenta (linagliptine)

11 October 2011

Oracea (doxycycline)

Low-dose treatment alternative for rosacea patients

20 September 2011

Eliquis (apixaban)

The 3rd oral drug for prophylaxis of thromboses after orthopedic surgery

29 August 2011

Pradaxa (dabigatran)

Should it replace oral anticoagulant treatment in patients with atrial fibrillation?

29 August 2011

Xeplion (paliperidone palmitate)

09 August 2011

Sativex (Delta(9)-tetrahydrocannabinol, Cannabidol)

28 June 2011

Visanne (Dienogest)

17 June 2011

Trobalt (retigabine)

01 June 2011

Vaniqa cream 11,5% (eflornithine)

26 April 2011

Versatis (lidocaine patch)

06 April 2011

Flavamed (ambroxol)

06 April 2011

When new products that are of general medical interest enter the Danish market or there are special changes made in already marketed products, the Institute for Rational Pharmacotherapy prepares a short description of how the product should be used within a context of the other available therapies.

Go to Reviews

Selected webpages

From the Danish Medicines Agency and IRF:

Page last updated: 15 May 2013

Institut for Rationel Farmakoterapi - Axel Heides Gade 1 - 2300 København S - tlf. +45 44 88 91 21 - E-mail: